The global lyme disease testing market size was estimated at USD 10.85 billion in 2023 and is projected to reach USD 18.57 billion by 2030, growing at a CAGR of 8.2% from 2024 to 2030. The market’s expansion is driven by several critical factors, reflecting the growing need for accurate and timely diagnosis of the disease.

A primary driver of market growth is the rising incidence of Lyme disease, particularly in regions such as North America and Europe. This increasing prevalence has led to a heightened demand for reliable diagnostic tools capable of detecting the disease at early stages. Growing public and professional awareness about Lyme disease, its symptoms, and potential long-term complications has further contributed to market expansion. For example, in June 2024, Valneva SE announced the results of Phase 2 trials for its Lyme disease vaccine candidate, VLA15, published in The Lancet Infectious Diseases. These trials demonstrated that VLA15, targeting six Borrelia serotypes, was highly immunogenic and exhibited a favorable safety profile, highlighting ongoing advancements in disease prevention and treatment.

Additionally, climate changes are expanding the habitats of ticks, the primary vectors of Lyme disease, which is facilitating the spread of the disease to new geographic areas. This broader distribution increases exposure risks and underscores the importance of accessible and effective diagnostic tests. According to the Centers for Disease Control and Prevention (CDC), approximately 476,000 Americans are diagnosed with Lyme disease annually, emphasizing the substantial domestic burden.

These factors have spurred significant initiatives to improve diagnostic accuracy, resulting in technological advancements such as multiplex PCR assays and enhanced immunoassays. These tools are crucial for early and precise detection, allowing for timely treatment and better patient outcomes. Furthermore, the World Health Organization (WHO) recognizes Lyme disease as endemic in over 80 countries, reflecting its global impact. The rising number of cases worldwide underscores the pressing need for reliable testing, driving continued growth in the Lyme disease testing market.

Key Market Trends & Insights:

• In 2023, Europe emerged as the dominant region in the Lyme disease testing market, accounting for the largest revenue share of 48.22%. The region’s leadership can be attributed to the high prevalence of Lyme disease in several European countries, well-established healthcare infrastructure, advanced diagnostic facilities, and strong public awareness initiatives aimed at early detection and treatment of the disease.

• Within Europe, France is expected to experience the fastest growth rate during the forecast period. The rapid expansion in the French market is driven by increasing incidence rates, growing awareness among healthcare professionals and the public, and significant investments in advanced diagnostic technologies to improve early detection and patient outcomes.

• When analyzed by technology, the “other” segment held the largest revenue share of 88.6% in 2023. This segment encompasses advanced and emerging diagnostic technologies beyond conventional methods, highlighting the market’s focus on innovative testing approaches that enhance accuracy, sensitivity, and reliability.

• By testing type, the serological test segment dominated the market with a revenue share of 53.1% in 2023. Serological tests are widely used for detecting antibodies against Borrelia bacteria, the causative agent of Lyme disease, making them a preferred choice for clinicians and laboratories due to their efficiency and diagnostic reliability.

• Regarding sample type, blood samples led the market with a revenue share of 62.4% in 2023. Blood is the most commonly used sample for Lyme disease testing as it allows for the detection of antibodies or DNA of the pathogen, facilitating early diagnosis and guiding appropriate treatment interventions. This high adoption underscores the critical role of blood-based testing in the global Lyme disease diagnostics landscape.

Order a free sample PDF of the Lyme Disease Testing Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2023 Market Size: USD 10.85 Billion

• 2030 Projected Market Size: USD 18.57 Billion

• CAGR (2024-2030): 8.2%

• Europe: Largest market in 2023

Key Companies & Market Share Insights:

The Lyme disease testing market is defined by a highly competitive landscape, with several leading companies holding substantial market shares. These key players focus on the development, commercialization, and continuous improvement of advanced diagnostic tests aimed at enhancing the detection and management of Lyme disease. Their product portfolios typically include serological assays, polymerase chain reaction (PCR) tests, and other innovative diagnostic methodologies designed to improve both the accuracy and speed of diagnosis.

A notable trend in the market is the increasing integration of molecular diagnostic technologies. These approaches, which include advanced PCR-based assays and other nucleic acid detection methods, offer higher sensitivity and specificity compared to traditional serological tests. By enabling earlier and more precise detection of the Borrelia bacteria, molecular diagnostics are significantly improving patient outcomes and shaping the future of Lyme disease testing. As companies continue to invest in research and development, the adoption of these advanced technologies is expected to further strengthen market growth and competitive differentiation.

Key Players

• DiaSorin S.p.A

• BIOMÉRIEUX

• Oxford Immunotec

• Bio-Rad Laboratories, Inc.

• Thermo Fisher Scientific, Inc.

• T2 Biosystems

• IGeneX

• Gold Standard Diagnostics

• ZEUS Scientific

• Trinity Biotech

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The Lyme disease testing market is experiencing significant growth, driven by the increasing prevalence of the disease, particularly in North America and Europe. This rise in cases has heightened the demand for accurate and efficient diagnostic tools. Advancements in testing technologies, such as multiplex PCR assays and enhanced immunoassays, are improving early detection and treatment outcomes. Additionally, growing public awareness and education about Lyme disease are contributing to the market's expansion. The market is characterized by a competitive landscape with several key players holding significant market shares. These companies are focusing on developing and commercializing advanced diagnostic tests, including serological assays, PCR tests, and other innovative methodologies to enhance accuracy and speed in diagnosing Lyme disease.